Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Atropine-induced intraocular pressure changes and anterior segment structural parameters in dogs assessed by ultrasound biomicroscopy.

Frontiers in veterinary science·2026

Same author

Homozygous CHD8 mutation intensifies ASD phenotypes and attenuates sex differences.

Molecular psychiatry·2026

Same author

De novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics.

Experimental & molecular medicine·2026

Same author

From Coplanarity to Coaxiality: A Linearity-Oriented Design Paradigm for Ultrahigh Ultraviolet Birefringent Inorganic Crystals.

Journal of the American Chemical Society·2026

Same author

Transcriptomic profiling of chlorogenic acid and taurine treatment in human skin cells provides insights into cellular senescence mechanisms.

Frontiers in molecular biosciences·2026

Same author

Bazedoxifene reverses sexually dimorphic autistic-like abnormalities in biallelic MDGA1-mutant mice.

EMBO molecular medicine·2026

Same journal

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.

mAbs·2026

Same journal

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

mAbs·2026

Same journal

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026

Same journal

Development of single-chain C1q affinity chromatography-mass spectrometry for the glycoform-resolved characterization of low-affinity immunoglobulin G interactions.

mAbs·2026

Same journal

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

mAbs·2026

Same journal

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

mAbs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 15, 2025

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Artificial intelligence-driven computational methods for antibody design and optimization.

Luiz Felipe Vecchietti¹, Bryan Nathanael Wijaya², Azamat Armanuly³

¹Max Planck Institute for Security and Privacy (MPI-SP), Universitätsstraße 140, Bochum, Germany.

|July 18, 2025

Summary

This summary is machine-generated.

Artificial intelligence (AI) is revolutionizing antibody design by generating novel antibody sequences and structures. This AI-driven approach accelerates the development of therapeutic and diagnostic antibodies against specific targets.

Keywords:

Antibody design generative artificial intelligence machine learning protein design structural biology

More Related Videos

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Related Experiment Videos

Last Updated: Sep 15, 2025

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Area of Science:

Immunology
Computational Biology
Drug Discovery

Background:

Antibodies are key components of the immune system, essential for neutralizing pathogens.
Developing therapeutic and diagnostic antibodies is crucial but traditionally time-consuming and costly.
Computational methods offer a pathway to accelerate antibody design and development.

Purpose of the Study:

To review current artificial intelligence (AI) methods applied to antibody development.
To focus on AI techniques for antigen-conditioned antibody design.
To highlight the potential of AI in generating de novo antibody binders.

Main Methods:

Survey of recent advancements in AI for protein sequence and structure generation.
Application of generative AI models to design antibodies for specific antigen targets.
Experimental validation of de novo-designed antibodies.

Main Results:

AI methods have demonstrated success in generating novel protein scaffolds and binders.
Generative AI has been successfully applied to antigen-conditioned antibody design.
Experimental validation confirmed the binding capabilities of de novo-designed antibodies.

Conclusions:

AI-based methodologies show significant promise for antibody and protein research.
These methods offer a powerful new direction for generating de novo binders against diverse antigens.
AI is poised to revolutionize antibody drug discovery by reducing development time and costs.